回盛生物修订公司章程，完善公司治理体系

Core Points - Wuhan Huisheng Biotechnology Co., Ltd. has revised its company articles to enhance governance and protect the rights of stakeholders [1][2] - The company was registered on July 27, 2020, and went public on August 24, 2020, with a registered capital of RMB 202.332557 million [1] - The revision includes detailed rules on share management, shareholder rights and obligations, board structure, and management responsibilities [2] Share Management - The total number of shares is 202.332557 million, all of which are ordinary shares [1] - The company has established rules for share issuance, reduction, repurchase, and transfer, ensuring equal rights for the same class of shares [1] - Specific restrictions on share transfer are in place, such as a one-year lock-up period for shares issued before the public offering [1] Shareholder and Shareholder Meeting - The rights and obligations of shareholders, as well as the responsibilities of controlling shareholders and actual controllers, are clearly defined [2] - Shareholders have rights to dividends and participation in shareholder meetings, while also being obligated to comply with the articles and pay share capital [2] - The shareholder meeting has decision-making authority on major company matters, including electing directors and approving profit distribution [2] Board of Directors - The board consists of five directors, including two independent directors and one employee director [2] - The board is accountable to the shareholder meeting and has various powers, including convening meetings and executing resolutions [2] - Detailed responsibilities and operations for independent directors and board committees are outlined [2] Senior Management - The company appoints one general manager and several deputy managers, with clear qualifications and responsibilities for senior management [2] - The articles also cover financial accounting, profit distribution, auditing, and procedures for corporate actions such as mergers and dissolutions [2] Conclusion - The revision of the company articles is a significant step for Huisheng Biotechnology to adapt to its development and market changes, aiming to improve governance and ensure sustainable operations [2]